Dyslipidemie
.webp/jcr:content/Cardio2_cover%20(2).webp)
Artikelen
Prevent the Event
Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.1
Lipid management in patients with diabetes mellitus
Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice
A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.
Why choose PRALUENT®?
The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
Opleiding
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262
Why Don’t We Strike Early, Strike Strong?
Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens
.svg)
.svg)
Bevestig uw status
Bevestig uw status
Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal
speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een ljst met
evenementen en tools en diensten voor uw dagelijkse praktik.